Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

The Call Bristol-Myers Squibb Bulls Got Right - Yahoo Finance

Drug pricing Financial outlook Patent expiry AI-generated analysis

📈 Bristol-Myers Squibb shares rose 46.5% over the past year to trade at US$61.48, reflecting strong Q2 2026 performance with revenue of US$12,973m and net income of US$3,317m.

📊 The company achieved a net margin of 25.6% in Q2 2026, up significantly from 10.7% a year earlier, aligning with optimistic valuation assumptions of a 22.4% target margin.

⚠️ Bearish analysts warn that loss of exclusivity for key drugs like Eliquis and Opdivo combined with pricing pressure could continue eroding the revenue mix and margin profile.

🔬 The investment case hinges on converting the late-stage pipeline, including assets milvexian, admilparant, arlo-cel, and CELMoDs, into durable revenue to offset blockbuster declines.

💰 Optimistic valuation models price BMY at a Fair Value of US$53 based on 14.4x future P/E, while cautious views suggest a lower value of US$34 due to debt concerns.

📉 Investors must verify if margin expansion comes from the core portfolio or one-off shifts by tracking net margins in upcoming filings against company claims.

Bullish Signals
  • Bristol-Myers Squibb delivered strong Q2 2026 results with revenue rising to US$12,973m and net income reaching US$3,317m, marking a significant improvement over the prior year.
  • The company achieved a robust net margin of 25.6% in Q2 2026 compared to 10.7% a year earlier, validating optimistic assumptions about profitability expansion.
  • Shares have appreciated 46.5% over the past year, trading at US$61.48, indicating market confidence that the late-stage oncology portfolio is successfully replacing earnings from aging blockbusters.
Risk Factors
  • Bearish analysts expect loss of exclusivity and pricing pressure on key drugs to continue eroding Bristol-Myers Squibb's revenue mix and margin profile despite newer portfolio growth.
  • The company faces ongoing concerns regarding trial delays, safety questions, and timelines for late-stage assets like milvexian and admilparant that could challenge a smooth handover of earnings.
Full Analysis
Bristol-Myers Squibb (BMY) shares have gained 46.5% over the past year, trading at US$61.48 after Q2 2026 results showed revenue rising to US$12,973m and net income reaching US$3,317m. This performance aligns with optimistic valuation models that project a 22.4% profit margin and a 14.4x future P/E ratio, suggesting the market has priced in successful delivery from the late-stage oncology portfolio despite lingering concerns about patent cliffs on key assets like Eliquis and Opdivo. The article highlights a divergence between bullish and bearish narratives regarding BMY's future value. While optimistic views assume newer drugs will seamlessly replace earnings from aging blockbusters, cautious analysts warn that loss of exclusivity and pricing pressure could erode the revenue mix and margin profile. The core investment thesis relies on the company's ability to convert its large late-stage pipeline—including assets like milvexian, admilparant, and CELMoDs—into durable post-loss-of-exclusivity revenue that offsets potential setbacks, delays, or safety concerns. Investors are advised to track net margin in filings against claims of expansion to ensure higher earnings stem from the core portfolio rather than one-off shifts. The broader lesson for drug makers is the necessity of a spread of therapies across specialties to mitigate reliance on single blockbusters. While BMY faces challenges regarding trial delays and safety questions, the current market price implies confidence that the newer portfolio will sustain growth even as patent protections expire.